Immune Targeting Systems Secures an GBP 8.65m Series A Extension to Fund FP-01, Its Synthetic Universal Flu Vaccine Through PhII

Immune Targeting Systems (ITS) Ltd. Secures an GBP 8.65m Series A Extension to Fund FP-01, Its Synthetic Universal Flu Vaccine Through Phase-II Studies
FP-01 expected to enter phase-I in 2010 

LONDON, Feb 17, 2010 (BUSINESS WIRE) -- Immune Targeting Systems (ITS) Limited ("ITS"), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for GBP 8.65m which brings the total Series A financing to GBP 13.15m. The company's key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest.

This funding will progress ITS's lead candidate FP-01 through to the completion of phase-II proof of concept efficacy studies. This vaccine holds the promise of being able to target all potential seasonal and pandemic influenza strains and protect people from severe influenza disease. The synthetic and thermostable FP-01 vaccine would offer a new paradigm in flu vaccine supply and could represent a major breakthrough to Governments wishing to create long-term vaccine stockpiles.

Carlton Brown, CEO of ITS, commented: "This round of financing will allow the company to evaluate its flu vaccine product candidate in phase I and Phase II clinical trials and assess the vaccine safety and preliminary efficacy against multiple influenza virus strains".

Ken Powell, ITS's Chairman commented: "This sound support of ITS and its exciting clinical programmes shows that there is funding available for high quality teams and projects in 2010 and should give encouragement to other UK biotechnology companies".

Florent Gros, Managing Director at Novartis Venture Fund commented: "We believe strongly in the need to enhance T-cell immunity in vaccinology, and we are delighted that ITS is advancing its unique technology and lead program to clinical validation."

Jacob Gunterberg Partner at HealthCap: "In the vaccine field this is a unique global problem solving vaccine technology and its potential to hit mutating viruses in their Achilles heel is a major breakthrough. We like management's philosophy of delivering milestones and managing risk."

Philippe Pouletty, MD, General Partner of Truffle Capital added: "We strongly believe novel technologies can allow vaccine protection against multiple seasonal and pandemic flu viruses and ITS pursues a very promising approach".

David McMeekin, Chairman of the London Technology Fund, said, "This further funding is an important endorsement of ITS's technology and we are delighted to see a London-based business like this continue to attract funding from such a strong group of investors".

SOURCE: Immune Targeting Systems


Corporate Inquiries
London Bioscience Innovation Centre
Carlton Brown, CEO
Tel +44 7970 944 454
Email: [email protected]
or
Media Inquiries
Schwartz Communications
Richard Hayhurst
Tel +44 (0) 7711821527
Email: [email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.